When combined with either anti-CTLA or anti-PD1 therapy, marked improvement in tumor regression along with a significant improvement in survival was seen compared with single agent STING agonist (8803) therapy alone (p = 0.001 vs. p = 0.008) [66]. The gene discussed is PDCD1; the disease is neoplasm.